Is Furazolidone Therapy for Helicobacter pylori Effective and Safe?
- 72 Downloads
We have read with great interest the study performed in Pakistan by Abbas et al.  on the efficacy and safety of a “rescue” therapy to cure Helicobacter pylori infection. Briefly, following a quadruple therapy including high-dose esomeprazole, bismuth salts, amoxicillin-clavulanic acid, and furazolidone, an 81% eradication rate was achieved at ITT analysis, with a side-effects incidence as high as 50%. The authors concluded that “it is reasonably well tolerated and is an effective second-line regimen” and even suggested it could be used as a first-line therapy. We have some concerns about these conclusions. First, following the first-line therapy, H. pylorieradication was achieved in 119 (67.6%) out of 176 enrolled patients. Consequently, 57 eradication failure patients were available instead of 52, as was reported. If all these patients received a second-line therapy, then both ITT and PP analysis should be accordingly calculated. Second, the reported side-effects incidence (up to...
KeywordsBismuth Proton Pump Inhibitor Pylorus Infection Triple Therapy Esomeprazole
- 1.Abbas Z, Yakoob J, Abid S, et al. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig Dis Sci. 2008 Dec 5 (Epub ahead of print).Google Scholar
- 5.Tatsuta M, Iishi H, Baba M, Taniguchi H. Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1991;48:605–608. doi: 10.1002/ijc.2910480420.PubMedCrossRefGoogle Scholar
- 8.Taghavi SA, Jafari A, Eshraghian A. Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-Amoxiclav, and omeprazole in Iranian Patients. Dig Dis Sci. 2009;54(3):599–603 Jul 2 (Epub ahead of print).Google Scholar
- 11.Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, Kang KW, Lee ES, Choi HG, Yong CS, Kim JA. The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol 2009;50(3-4):123–131 Nov 28 (Epub ahead of print).Google Scholar